Penalty on US company for paying less to H-1B employees

Agencies
September 14, 2018

Washington, Sept 14: A Redmond-based information technology staffing company was asked to pay over USD 300,000 to its 12 H-1B employees for paying them far below their salary and has been imposed a penalty of over USD 45,000, a media report said on Thursday.

The US Department of Labour Wage and Hour Division (WHD) during the investigation found the company, which has offices in Bengaluru and Hyderabad, violated the labour provisions of the H-1B visa program by paying its guest workers far below the required wages, the report said.

As a result, People Tech Group Inc has been asked to pay its 12 employees USD 309,914 and has been slapped with a penalty of USD 45,564, it said.

Investigators found that the company paid entry-level wages to H-1B computer analysts and computer programmers who performed the work of much more experienced employees and should have received higher prevailing rates, the Department of Labour said.

The Group also did not pay the employees for the time when it failed to provide them work, as the law requires, the department said.

"The intent of the H-1B foreign labour certification program is to help American companies find the highly skilled talent they need when they can prove that a shortage of US workers exists," said Wage and Hour Division Acting District Director Carrie Aguilar in Seattle.

The resolution of this case demonstrates our commitment to safeguard American jobs, level the playing field for law-abiding employers, and ensure no one is being paid less than they are legally owed, Aguilar said.

The Wage and Hour Division has listed nearly 30 companies as willful violator employers under the H-1B program.

As per the list maintained since 2013, a majority of willful violators are Indian Americans or companies owned by them. At least 10 companies, which includes eight willful violators have been debarred or disqualified from hiring foreign guest workers on H-1B visas.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 8,2024

covid.jpg

AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the pandemic.

The company also said it would proceed to withdraw the vaccine Vaxzevria's marketing authorizations within Europe.

"As multiple, variant Covid-19 vaccines have since been developed there is a surplus of available updated vaccines," the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.

According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.

The firm's application to withdraw the vaccine was made on March 5 and came into effect on May 7, according to the Telegraph, which first reported the development.

London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.